The Centers for Medicare & Medicaid Services is launching a new initiative for state Medicaid programs to purchase prescription drugs at prices aligned with those paid in other countries, known as most-favored-nation pricing. The program, called the GENErating cost Reductions fOr U.S. (GENEROUS) Medicaid Model, will be coordinated by the CMS Innovation Center. CMS said it will issue a request for applications later this fall for drug manufacturers interested in participating in the model. The agency will also seek letters of intent from interested state Medicaid agencies.

Related News Articles

Chairperson's File
Public
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
Headline
The Centers for Medicare & Medicaid Services released a bulletin Nov. 18 summarizing provisions from the budget reconciliation bill related to Medicaid and…
Headline
Aetna’s new “level of severity inpatient payment” policy is now set to take effect Jan. 1, 2026, the company recently announced, along with providing…
Headline
Medicaid enrollment decreased 7.6% in fiscal year 2025 and is expected to be mostly flat in FY 2026, according to KFF’s annual Medicaid Budget Survey released…
Blog
Public
The health care field has entered a period of disruption, from sweeping coverage changes to the rise of artificial intelligence (AI)-enabled tools. The…
Chairperson's File
Public
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…